SI-BONE, Inc. (SIBN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong growth prospects with updated revenue guidance, new product launches, and international expansion plans. The partnership with Smith & Nephew and positive clinical data further support market development. Despite a slight EBITDA miss and gross margin compression, the optimistic guidance and strategic initiatives indicate a positive outlook. The Q&A session did not reveal major concerns, and the market strategy seems solid, suggesting a positive stock price movement in the near term.
Key Financial Performance
Annual worldwide revenue Nearly $201 million, marking over 20% growth year-over-year. This growth was driven by increased physician engagement, expanded utilization, and strengthened reimbursement positions.
U.S. revenue (Q4) $53.5 million, representing 13.9% growth year-over-year. Growth was against a tough comparable prior year quarter and driven by increased procedure volumes.
International revenue (Q4) $2.9 million, growing 38.8% year-over-year. Growth was driven by strong reception for iFuse TORQ.
Full year U.S. revenue $191.1 million, reflecting 20.6% growth year-over-year. Growth was driven by a 22% increase in procedure volume.
Full year international revenue $9.8 million, reflecting strong growth driven by product adoption.
Gross profit (Q4) $44.5 million, increasing 14.8% year-over-year. Growth was supported by stable ASP, favorable procedure mix, and operational initiatives.
Full year gross profit $159.9 million, increasing 21% year-over-year. Growth was driven by stable ASP, favorable procedure mix, and operational efficiencies.
Gross margin (Q4) 79%, consistent with the full year gross margin of 79.6%. This was approximately 200 basis points above original guidance due to operational efficiencies.
Operating expenses (Q4) $47 million, growing 6.2% year-over-year. Growth was driven by revenue-generating activities, including higher sales commissions and increased R&D investment.
Net loss (Q4) $1.6 million, narrowing from $4.5 million in the prior year. Improvement was due to increased revenue and operational efficiencies.
Net loss (Full year) $18.9 million, narrowing by 38.8% year-over-year. Improvement was driven by revenue growth and cost management.
Adjusted EBITDA (Q4) $5.1 million, a 176.2% improvement year-over-year. This reflects a 9.1% adjusted EBITDA margin, highlighting scalability.
Adjusted EBITDA (Full year) $8.9 million, compared to a $5.1 million loss in 2024. This represents a $14 million improvement year-over-year.
Cash and equivalents (End of 2025) $147.8 million, an increase of $2.1 million from the prior quarter. Improvement was due to positive cash flow from operating activities and disciplined working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA breakthrough device designation: Three products have been granted FDA breakthrough device designation, showcasing innovation in solving complex procedural challenges.
New product launch: Launched INTRA Ti, a new addition to the SI Joint Fusion platform, with expected adoption ramping up in 2026.
Future product pipeline: A third breakthrough device is on track for 510(k) clearance in Q3 2026, with commercialization expected in late 2026.
Revenue growth: Achieved record annual worldwide revenue of nearly $201 million in 2025, marking over 20% growth.
Physician engagement: 22% increase in U.S. physicians using technologies, with over 2,400 physicians performing nearly 22,000 procedures in 2025.
Strategic partnership: Entered into a partnership with Smith & Nephew to expand reach in the trauma market.
Profitability: Delivered first full year of positive adjusted EBITDA in 2025, with a 9% adjusted EBITDA margin in Q4.
Cash flow: Achieved positive free cash flow in Q4 2025, with significant improvement in cash consumption compared to 2024.
Operational efficiency: Improved supply chain efficiency and cost optimization contributed to a gross margin of 79.6% for 2025.
Market leadership: Maintained leadership in the sacroiliac joint fusion market and expanded into new adjacencies in the sacropelvic space.
Innovation focus: Positioned for an innovation super cycle over the next 5 years, targeting new clinical adjacencies and unmet patient needs.
Sales model: Hybrid sales model combining direct sales force and third-party agents has driven productivity and operating leverage.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Reimbursement Risks: The company's reliance on favorable reimbursement policies, such as NTAP and TPT, poses a risk if these policies change or are not renewed. Additionally, the company depends on CMS policy changes, which could impact outpatient migration and reimbursement levels.
Market Competition: The company faces competitive pressures in the sacropelvic and trauma markets, which could impact its market share and pricing power. The entry of new competitors or innovations by existing competitors could pose challenges.
Product Launch and Adoption Risks: The success of new products like INTRA Ti and the upcoming breakthrough device depends on physician adoption and training. Delays in adoption or negative feedback could impact revenue growth.
Supply Chain and Operational Risks: While the company has improved supply chain efficiency, any disruptions or cost increases could impact profitability and operational performance.
Economic and Market Conditions: Economic uncertainties or changes in healthcare spending could impact procedure volumes and overall revenue growth.
Strategic Execution Risks: The company's ability to scale its operations, expand its sales force, and execute its hybrid sales model effectively is critical. Any missteps in these areas could hinder growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Worldwide revenue for 2026 is expected to be between $228.5 million and $232.5 million, representing a year-over-year growth of 14% to 16%. U.S. procedure volume is anticipated to grow in the high teens.
Product Launches: The company plans to commercialize its next breakthrough device in late 2026, which is expected to expand the total addressable market. Additionally, the INTRA Ti product, launched in early 2026, is expected to ramp up adoption throughout the year.
Reimbursement Updates: Effective January 1, 2026, Medicare reimbursement for the OBL site of care increased by 17%, and CMS created a new Level 7 musculoskeletal APC, paying nearly $28,000 for certain outpatient spine procedures. These changes are expected to support outpatient migration in spine and enhance the economic attractiveness of minimally invasive SI Joint Fusion.
Operational and Financial Outlook: Gross margin for 2026 is expected to be approximately 78%. Operating expenses are projected to grow by 12.5% at the midpoint of the revenue range, with increased adjusted EBITDA and continued free cash flow generation.
Market Expansion: The company plans to add 10 new territories in 2026 and expand strategic agent partnerships to capture market opportunities. A strategic partnership with Smith & Nephew is expected to accelerate penetration into the trauma market.
Physician Engagement: The company expects to continue double-digit growth in physician adoption, with future products attracting new physicians and increasing procedural density among the existing physician base.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How did the Smith & Nephew partnership come about, and what is its potential contribution?
A:The partnership with Smith & Nephew builds on SI-BONE's hybrid sales model, which has expanded access to their solutions and improved productivity. Smith & Nephew has a significant trauma footprint, while SI-BONE focuses on spine and interventional. The partnership covers Level 1 and Level 2 trauma centers, allowing trauma surgeons to access SI-BONE's solutions for sacral insufficiency fractures. It frees up SI-BONE's direct sales force to focus on market development and physician engagement. However, the financial impact is not yet included in the guidance as it is too early to assess.
Q:Does the clinical data showing similar outcomes for IPM physicians and direct surgeons help create more engagement?
A:Yes, the clinical data, including the STACI study, shows that interventionalists using SI-BONE's TORQ product achieve similar outcomes to direct surgeons. This supports engagement with interventionalists, and the INTRA Ti product aligns with their preferred workflow, driving procedural efficiency in ambulatory surgery centers.
Q:Is the adjusted EBITDA guidance for 2026 around $20 million?
A:No, the adjusted EBITDA for 2026 is expected to be slightly below $20 million. The company is focusing on growth investments, including new product commercialization, European expansion, and R&D, which impacts operating leverage.
Q:What is the potential halo effect of the INTRA Ti product in the ASC setting?
A:The INTRA Ti product is expected to expand the market by providing interventional spine physicians with a posterior metal implant solution. It addresses reimbursement gaps in 22 states and serves physicians preferring non-allograft solutions. The product is in alpha launch, with adoption expected to ramp through 2026.
Q:What is the revenue cadence for 2026, and what tailwinds are expected?
A:Revenue growth is expected to be back-half weighted in 2026 due to tailwinds such as an expanded physician base, improved reimbursement, new product launches (e.g., INTRA Ti), and commercial expansion. Quarterly guidance is not provided, but the company anticipates these factors to materialize throughout the year.
Q:Will the company grow faster over the next 5 years compared to the last 5 years?
A:The company has achieved 20% average revenue growth since its IPO and expects to sustain or potentially accelerate growth over the next 5 years. This is driven by innovative solutions targeting unmet clinical needs in spine and interventional markets, with a regular cadence of product launches.
Q:Why is the 2026 guidance showing a sequential slowdown despite tailwinds?
A:The guidance reflects high teens growth in procedure volume, with a slight ASP degradation due to product mix. The slowdown is attributed to tough comparisons from 2025 and a cautious approach to incorporating new product impacts early in the year.
Q:What is the company's presence in the ASC market, and how will INTRA Ti impact it?
A:Currently, 35% of SI Joint Fusion sales occur in ASCs, up from virtually none five years ago. The INTRA Ti product is expected to drive further growth in the ASC market due to its simplicity, single-use system, and alignment with interventional spine physicians' workflows.
Q:How is the company strategically adding new territories for commercial expansion?
A:The company identifies underpenetrated areas with significant opportunities in spine and interventional markets. It plans to add 10 territories in 2026, balancing direct sales force growth with hybrid sales models. About 50% of new territory managers are promoted internally.
Q:What is the impact of the Smith & Nephew partnership on the cadence of 2026?
A:The partnership is expected to ramp up in Q2 and Q3, with initial activity starting in March. The focus is on training, placing implants, and instrument trays, with significant activity anticipated in Q4.
Q:What are the drivers of the 160 basis points gross margin compression in 2026?
A:The compression is primarily due to noncash impacts from depreciation related to increased surgical capacity for new products and partnerships. ASP pressure is offset by operational initiatives to reduce costs.
Q:Why is the high teens U.S. volume growth guidance appropriate for 2026?
A:The guidance reflects tough comparisons from 2025 and a cautious approach to incorporating new product impacts. The company expects growth to accelerate as new products and partnerships ramp up.
Q:What is the marginal profit impact of the Smith & Nephew partnership?
A:The company did not disclose specific profit details but emphasized the partnership's multifaceted benefits, including expanding access to Level 1 and Level 2 trauma sites and freeing up the direct sales force for other growth opportunities.
Q:Review of Unclear Management Responses
A:Management avoided providing specific financial details for the Smith & Nephew partnership's marginal profit impact and the adjusted EBITDA guidance for 2026, offering only general comments about the partnership's strategic benefits and growth investments.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Anshul update
Bedrock Granite
Commercial
INTRA Ti
Joint Fusion
Officer
SI Joint
TORQ TNT
Vice President
activity sale
adjacency
cash consumption
center
challenge outcome
commitment
cost
effort
excellence
expertise
function
leader
market iFuse
market opportunity
outcome patient
patient bone
physician adoption
platform technology
reputation
role Chief
site care
stack
success
utilization
week
SIBN Transcript
SI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
SI-BONE, Inc. (SIBN) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call highlights strong revenue growth, product launches, and strategic partnerships, which are expected to drive future expansion. The Q&A session reveals a conservative guidance increase, but potential upside from new products and partnerships. Although some uncertainties remain, such as specific 2027 growth rates and financial impacts, the overall sentiment is positive due to strong margins, increased reimbursement, and international growth potential.
SI-BONE, Inc. (SIBN) Q4 2025 Earnings Call Transcript
Positive2-23
The earnings call highlights strong growth prospects with updated revenue guidance, new product launches, and international expansion plans. The partnership with Smith & Nephew and positive clinical data further support market development. Despite a slight EBITDA miss and gross margin compression, the optimistic guidance and strategic initiatives indicate a positive outlook. The Q&A session did not reveal major concerns, and the market strategy seems solid, suggesting a positive stock price movement in the near term.
SI-BONE, Inc. (SIBN) Q3 2025 Earnings Call Transcript
Positive11-10
The company raised its guidance midpoint due to strong Q3 performance and expects continued positive momentum in Q4. They achieved positive cash flow from operating activities and have a strong product pipeline with international growth prospects. Gross margins exceeded expectations, and they anticipate further improvement. Despite some vague responses, the overall sentiment from the Q&A is positive, with strong growth drivers and strategic initiatives in place.
SIBN Slides
SI-BONE Q1 2026 slides: profitability surges, physician base expands2026-05-11
SI-BONE Q4 2025 slides: profitability milestone as revenue tops $200M2026-02-23
SI-BONE Q2 2025 slides: Revenue jumps 22%, raises full-year guidance2025-08-04
Si-Bone Q1 2025 slides: revenue jumps 25%, achieves positive EBITDA2025-05-05
SIBN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
